NASDAQ:ICPT
Delisted
Intercept Pharmaceuticals Stock News
$19.00
+0 (+0%)
At Close: Feb 06, 2024
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
12:00pm, Wednesday, 27'th Jul 2022 GlobeNewswire Inc.
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutic
Biotech Stock Roundup: ICPT's Study Data, NVAX Vaccine Gets EUA, VERU Up on Data
04:13pm, Thursday, 14'th Jul 2022 Zacks Investment Research
Regulatory and other updates from Intercept (ICPT) and VERU are a few key highlights from the biotech sector during the past week.
Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path
04:53pm, Friday, 08'th Jul 2022 Benzinga
Yesterday, Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced data from the new interim analysis of the Phase 3 REGENERATE trial evaluating obeticholic acid in nonalcoholic steatohepatitis (NA
Intercept (ICPT) Reports Positive Data From NASH Study on OCA
03:12pm, Friday, 08'th Jul 2022 Zacks Investment Research
Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Intercept (ICPT) Reports Positive Data From NASH Study on OCA
12:25pm, Friday, 08'th Jul 2022
Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
04:02pm, Thursday, 07'th Jul 2022 Benzinga
Gainers
United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.
American
Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
03:23pm, Thursday, 07'th Jul 2022 Zacks Investment Research
Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.
Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
01:09pm, Thursday, 07'th Jul 2022
Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.
Why Did Intercept Pharmaceuticals (ICPT) Stock Fall 10% Today?
12:14pm, Thursday, 07'th Jul 2022
A fresh press release from Intercept Pharmaceuticals reveals positive data from an important clinical trial. Yet, ICPT stock is dropping.
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.
08:01pm, Friday, 01'st Jul 2022 GlobeNewswire Inc.
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics
Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again
02:57pm, Monday, 06'th Jun 2022
Intercept Pharmaceuticals Inc's (NASDAQ: ICPT) pre-submission meeting to discuss the marketing application for obeticholic acid (OCA) in NASH has been moved to July (vs. June scheduling).
Intercept: Increase Of Ocaliva Sales And A Few Catalysts
03:47pm, Monday, 23'rd May 2022
Final data from the phase 3 REGENERATE study, using Ocaliva for the treatment of patients with NASH fibrosis, is expected any day now. If all goes well with clinical data, Intercept expects a pre-subm
Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss Estimates
03:48pm, Monday, 09'th May 2022
Intercept (ICPT) posts a narrower-than-expected loss in the first quarter. Sales lag estimates.
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q1 2022 Results - Earnings Call Transcript
05:33pm, Friday, 06'th May 2022
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Nareg Sagherian - ED, IR Jerome Durso - President and CEO Andrew Saik - CFO
